Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Raltegravir

Raltegravir

Raltegravir is an integrase inhibitor medication used to treat HIV infection.
It works by blocking the HIV integrase enzyme, preventing the virus from incorporating its genetic material into the host cell's DNA.
This helps reduce viral load and slow the progression of HIV disease.
Raltegravir has demonstrated efficacy in treating both treatment-naive and treatment-experienced patients, making it a valuable option in the management of HIV.
Researchers can optimize their Raltegravir studies by utilizing PubCompare.ai's AI-powered protocols, which provide access to a wealth of literature, preprints, and patents to identify the most reproducible and precise methods.
PubCompare.ai's intelligent comparisons ensure researchers can experience unparalleled accuracy and efficency in finding the optimal protocols and products for their Raltegravr research.

Most cited protocols related to «Raltegravir»

1
Early Antiretroviral Therapy for Acute HIV
Cited 10 times
The RV254/SEARCH 010 study is an ongoing prospective, open-label study in Bangkok, Thailand (clinicaltrials.gov identification NCT00796146). The study was approved by the institutional review boards (IRBs) of Chulalongkorn University in Thailand and the Walter Reed Army Institute of Research in the United States. All subjects gave informed consent. Samples from subjects who had VCT for HIV at The Thai Red Cross Anonymous Clinic and at the Silom Community Clinic were screened in real-time by pooled NAT and sequential EIA according to published methods [13] (link). Thai subjects who fit the AHI laboratory criteria for Fiebig stages I to IV [14] (link) were enrolled (Figure 1) and had clinical and laboratory assessments at days 0, 2, 3, 5, 7, 10, weeks 2, 4, 8, 12, 16, 20, 24, and every 12 weeks thereafter up to 192 weeks. A checklist of ARS symptoms was employed by an HIV physician to assess all potential symptoms at the baseline and subsequent visits until all symptoms had resolved.
Laboratory assessments included CD4, HIV RNA, liver transaminases, creatinine, lipids and urinalysis. Plasma and peripheral blood mononuclear cells (PBMCs) were cryopreserved at all visits. Sampling of gut-associated lymphoid tissue (GALT) occurred at weeks 0 and 24 by sigmoidoscopy as an optional procedure (24 subjects at baseline and 13 subjects at week 24), and mucosal mononuclear cells (MMCs) were isolated from GALT.
Initiation of ART was voluntary and done as part of enrollment in an accompanying local protocol (clinicaltrials.gov identification NCT00796263), approved by the Chulalongkorn University IRB, and all subjects gave informed consent. Treatment was started on average 3 days (range 0–5 days) from enrollment. The regimen consisted of 5 antiretrovirals [tenofovir (TDF) 300 mg once daily, emtricitabine (FTC) 200 mg once daily, efavirenz (EFV) 600 mg once daily, raltegravir (RAL) 400 mg twice daily and maraviroc (MVC) 600 mg twice daily] for the first 24 weeks followed by simplification to 3 drugs with TDF, FTC and EFV. EFV was discontinued in subjects with intolerance or resistance, in which case dose adjustment of MVC to 300 mg twice daily was implemented. The first 10 subjects received the 5-drug regimen. Subsequently subjects were randomized 1∶1 (in a block of 30) to 5 drugs (MegaHAART) vs. 3 drugs (HAART with TDF, FTC, EFV) ART.
Ananworanich J., Schuetz A., Vandergeeten C., Sereti I., de Souza M., Rerknimitr R., Dewar R., Marovich M., van Griensven F., Sekaly R., Pinyakorn S., Phanuphak N., Trichavaroj R., Rutvisuttinunt W., Chomchey N., Paris R., Peel S., Valcour V., Maldarelli F., Chomont N., Michael N., Phanuphak P, & Kim J.H. (2012). Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection. PLoS ONE, 7(3), e33948.
Full text: Click here
Publication 2012
Antiretroviral Therapy, Highly Active Cells Creatinine efavirenz Lipids Liver Lymphoid Tissue Maraviroc Mucous Membrane PBMC Peripheral Blood Mononuclear Cells Pharmaceutical Preparations Physicians Plasma Proctosigmoidoscopy Raltegravir Tenofovir Thai Transaminases Treatment Protocols Urinalysis
2
Antiretroviral Efficacy and Safety in Treatment-Naive HIV-1 Patients
Cited 9 times
The PubMed/MEDLINE, Embase, and Cochrane databases were systematically searched (up to August 2013) to identify randomized controlled trials (RCTs) evaluating efficacy and/or safety of ATV/r, DRV/r, DTG, EFV, EVG/c, LPV/r, RAL, or RPV in treatment-naive HIV-1 patients. PubMed and EMBASE search terms were “HIV-1 [mesh] OR HIV infections [mesh] NOT pregnancy [mesh] AND ((dolutegravir OR GSK1349572) OR (efavirenz OR Sustiva OR Stocrin OR DMP-266) OR (raltegravir OR Isentress OR MK-0518) OR (elvitegravir OR GS-9137 OR JTK-303) OR (rilpivirine OR Edurant OR TMC 278) OR (darunavir OR Prezista OR TMC-114) OR (atazanavir OR Reyataz OR BMS-232632) OR (lopinavir OR ABT-378 OR Aluviran OR Koletra OR Kaletra) OR (Atripla OR Quad OR Stribild OR Eviplera OR Complera))”. The ClinicalTrials.gov registry, US FDA summary basis of approvals, EMA EPAR scientific discussions, and references of published systematic reviews and meta-analyses were also searched for any additional data. Abstracts of the 2013 meeting of the International AIDS Society and the Interscience Conference on Antimicrobial Agents and Chemotherapy were searched to identify recent presentations. Two phase 3 studies of DTG with data available after August 2013 were also included.
Study selection was conducted by two independent researchers who performed an initial review and selection of study titles/abstracts followed by full text review and selection. Disagreements between the reviewers were resolved by consensus. Pre-specified inclusion criteria included treatment-naive patients with HIV-1 infection; studies published in English; phase 3 or 4 RCT; patients aged ≥13 years; use of at least one of the third agents of interest; and reporting at least one of the efficacy outcomes of interest after 48 weeks of treatment. Non-randomized observational studies; single-arm studies; and studies examining different dosages of the same drug, structured treatment interruptions, maintenance treatments, or treatment switching were excluded, as were publications where outcomes specific to a treatment-naive population could not be distinguished. Studies reporting outcomes such that results could not be obtained for each treatment arm individually were also excluded. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed through all phases in the study [14] (link).
Three researchers independently abstracted data from the final selection of studies into a structured Microsoft Access database and data were reconciled for accuracy. The Effective Public Health Practice Project Quality Assessment, a quality assessment tool, was used to assess selection bias, study design, confounders, blinding, data collection methods, and withdrawals and dropouts [15] (link).
Patel D.A., Snedecor S.J., Tang W.Y., Sudharshan L., Lim J.W., Cuffe R., Pulgar S., Gilchrist K.A., Camejo R.R., Stephens J, & Nichols G. (2014). 48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis. PLoS ONE, 9(9), e105653.
Full text: Click here
Publication 2014
ABT 378 Acquired Immunodeficiency Syndrome Aftercare Atazanavir Atripla BMS 232632 Complera Conferences Darunavir DMP 266 efavirenz elvitegravir GS 9137 HIV-1 HIV Infections Infection Isentress JTK-303 Kaletra Lopinavir Microbicides MK 0518 Patients Pharmaceutical Preparations Pharmacotherapy Pregnancy Prezista Raltegravir Reyataz Rilpivirine Safety Stocrin Stribild Sustiva TMC 114 TMC 278
3
Tracking SIVmac239M Viral Replication
Cited 8 times
In total, 26 animals were intravenously infected with 2.2x105 IU (1mL) of transfection produced SIVmac239M. All 26 animals were used to enumerate the number of detectable barcodes measured during primary infection. Of these 26 animals, two animals were followed for over 3 months to assess early viral replication kinetics (peak and set point viral load) of SIVmac239M. Four of the other infected animals began antiretroviral treatment beginning at day 6 post infection and continued for 82 days. Each animal received a combination antiretroviral therapy (cART) regimen comprising a co-formulated preparation containing the reverse transcriptase inhibitors tenofovir (TFV: (R)-9-(2-phosphonylmethoxypropyl) adenine (PMPA), 20 mg/kg) and emtricitabine (FTC; 50 mg/kg) administered by once-daily subcutaneous injection, plus raltegravir (RAL; 150-200mg) given orally twice daily. At the time of interruption from cART, three animals were infused at the day of cART interruption with autologous CD8+ T cells transduced with an anti-SIV Gag T-cell receptor (animals MK9 and KTM) or with an irrelevant receptor (animals KMB and KZ2) plus daily subcutaneous injections of IL-2 at 10,000 IU/kg for 10 days. The total number of infused cells ranged from 4.6 to 6.4x109 cells with <1% of the cells CD4+. In these animals, infused cells did not traffic to lymphoid or GI tissues and persistence of the cells was poor. Animal KTM died due to procedural complications at the time of cART interruption and was therefore excluded from subsequent analyses. In a separate cohort of 6 animals (study 2), therapy was initiated on day 4 post-infection with the same therapeutic regimen (TFV, FTC, RAL) described above with the addition of the protease inhibitor indinavir (IDV; 120mg BID) and ritonavir (RTV; 100mg BID) for the first 9 months. In study 2, cART treatment was continued for 305, 374, or 482 days, with two animals discontinuing therapy at each time point. The remaining 14 animals were used to enumerate the number of replicating clonotypes during primary infection.
Fennessey C.M., Pinkevych M., Immonen T.T., Reynaldi A., Venturi V., Nadella P., Reid C., Newman L., Lipkey L., Oswald K., Bosche W.J., Trivett M.T., Ohlen C., Ott D.E., Estes J.D., Del Prete G.Q., Lifson J.D., Davenport M.P, & Keele B.F. (2017). Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. PLoS Pathogens, 13(5), e1006359.
Full text: Click here
Publication 2017
Adenine Animals CD4 Positive T Lymphocytes CD8-Positive T-Lymphocytes Cells Combination Antiretroviral Therapy glycosaminoglycan receptor Infection Kinetics Lymph Protease Inhibitors Raltegravir Reverse Transcriptase Inhibitors Subcutaneous Injections T-Lymphocyte Tenofovir Therapeutics Tissues Transfection Treatment Protocols Virus Replication
4
Rhesus Macaque SIV Infection and ART Suppression
Cited 8 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Animals Animals, Laboratory Autopsy Cells Darunavir Diet Disease Progression Females Herpesvirus 1, Cercopithecine Human respiratory syncytial virus Infection Institutional Animal Care and Use Committees isolation Macaca mulatta Maraviroc Metals Plasma Primates Proteins Raltegravir Ritonavir RNA, Viral Superinfection Tenofovir Therapeutics Treatment Protocols Tuberculosis Viremia Virus
5
Proficiency Testing of Antiretroviral Drugs
Cited 8 times
Every six months the CPQA PT program offered prepared plasma samples containing pre-specified concentrations (unknown to CPLs) of up to 21 ARV analytes: abacavir (ABC), amprenavir (APV), atazanavir (ATV), darunavir (DRV), didanosine (DDI), efavirenz (EFV), emtricitabine (FTC), etravirine (ETR), indinavir (IDV), lamivudine (3TC), lopinavir (LPV), maraviroc (MVC), nelfinavir (NFV), nevirapine (NVP), raltegravir (RGV), ritonavir (RTV), saquinavir (SQV), stavudine (D4T), tenofovir (TFV), tipranavir (TPV), zidovudine (ZDV). In each round and for each ARV, 5 concentrations, spanning an expected therapeutic range of each ARV, as well as occasional concentrations below or above, were provided. Samples are prepared by an outside subcontractor and tested by the CPQA lab prior to distribution. PT samples were stored at −70 ± 15°C and then shipped on dry ice to participating laboratories with detailed instructions. Upon arrival, each laboratory confirmed sample integrity and indicated planned reporting of specific analytes. Results were reported either through an online Laboratory Data Management System (LDMS) or via a template which was then uploaded into the LDMS database. At the end of the submission period, a completeness evaluation was performed to confirm that all planned results were received; discrepancies were queried for resolution. To summarize the proficiency of individual labs, a pre-specified scoring algorithm was applied to the RCs (see next paragraph). The scoring algorithm reflects US Clinical Laboratory Improvement Act (CLIA) PT regulations[13 (link)]. After review and approval by the CPQA advisory board chair, a final report was sent to the participating laboratories (with laboratories de-identified) and key leadership (laboratories identified per network leader).
An individual RC is deemed Acceptable provided a concentration is present where expected, and the concentration is within 20% of the final target (FT)[14 (link)]. (If a concentration is reported as below the lower limit of quantification (BLQ), and the run lower limit was below 80%*FT, the concentration was labeled Unacceptable.) For a given prepared sample, if the number of labs reporting for that sample is large enough, the variability between CPLs is small enough (≤15%) and the percent deviation of the group mean (GM, determined after removal of outliers, if any)from the weighed-in value (WIV) is >5%, the FT is set to the GM. Otherwise, FT is set to the WIV. At the analyte level, a CPL’sperformance is deemed Satisfactory for the round provided at least 80% of RCs are Acceptable. If the CPL score is <80% for an analyte, the CPL submits a corrective action plan to reestablish accuracy; a root cause is requested. Finally, in accordance with CLIA rules, a lab is classified as successful for an analyte provided the round-specific score was Satisfactory in at least 2 of the last 3 rounds (including the current).
DiFrancesco R., Rosenkranz S.L., Taylor C.R., Pande P.G., Siminski S.M., Jenny R.W, & Morse G.D. (2013). Clinical Pharmacology Quality Assurance (CPQA) Program: Models for Longitudinal Analysis of Antiretroviral (ARV) Proficiency Testing for International Laboratories. Therapeutic drug monitoring, 35(5), 631-642.
Publication 2013
abacavir amprenavir Atazanavir Clinical Laboratory Services Darunavir Dry Ice efavirenz etravirine Indinavir Lopinavir Maraviroc Nelfinavir Nevirapine Plant Roots Plasma Raltegravir Ritonavir Saquinavir Tenofovir Therapeutics tipranavir Zidovudine

Most recents protocols related to «Raltegravir»

1
HIV Integrase Strand Transfer Inhibitor Assay
The
assay for the detection of HIV-1 integrase strand transfer (ST) inhibitors
was adapted from previously described methods.21 (link) A double-stranded biotinylated donor DNA, corresponding
to the HIV U5 viral DNA end, was added to the wells of Streptavidin-coated
96-well microtiter plates (R&D systems). Following a 1 h incubation
at r.t. and three wash steps with PBS, purified recombinant integrase
(1 μM) was assembled using DTT (dithiothreitol, 1 M) onto the
preprocessed donor DNA through incubation for 30 min at 22 °C.
After the wash step, the test compounds and a positive control inhibitor
(Raltegravir, Merck) were added into individual wells at a final concentration
of 10 μM. The microtiter plates were incubated for 30 min at
37 °C and washed. The strand transfer reaction was initiated
through the addition of FITC-labeled target dsDNA (5′-TGACCAAGGGCTAATTCACT-FITC-3′
and 5′-AGTGAATTAGCCCTTGGTCA-FITC-3′).
The plates were incubated for a period of 1 h at 37 °C followed
by washing as before. An AP (Alkaline S2 phosphatase)-conjugated anti-FITC
secondary antibody (Sigma) was added and the plates were washed. The
chromogenic substrate (BluePhos, KPL) was added to allow for photometric
measurement at 620 nm using a microplate reader (xMark, Biorad). Percentage
inhibition was calculated utilizing the formula: where A620(Comp) = Absorbance at 620 nm with compounds, A620_No_integrase_control = Absorbance at 620 nm containing no enzyme, and A620_No_inhibitor_control = Absorbance at 620 nm containing
no inhibitor. All inhibition values are the average of triplicate
experiments.
Cardoza S., Yadav P., Ajmani A., Das P, & Tandon V. (2023). Synthesis of C3,C6-Diaryl 7-Azaindoles via One-Pot Suzuki–Miyaura Cross-Coupling Reaction and Evaluation of Their HIV-1 Integrase Inhibitory Activity. ACS Omega, 8(9), 8415-8426.
Publication 2023
Alkaline Phosphatase Antibodies, Anti-Idiotypic COMP protocol Dithiothreitol DNA, Double-Stranded DNA, Viral Enzymes Fluorescein-5-isothiocyanate Integrase p31 integrase protein, Human immunodeficiency virus 1 Psychological Inhibition Raltegravir Streptavidin Tissue Donors
2
HIV-Flow Assay for Enriched CD4+ T Cells
Enriched CD4+ T cells were processed for HIV-Flow assay50 (link). Briefly, after 1 h pre-incubation with 5 μg/ml Brefeldin A (BFA) and 24 h stimulation with of 162 nM PMA and 1 µg/ml ionomycin in the presence of ARVs (200 nM lamivudine and 200 nM raltegravir), extracellular staining was performed using the following antibodies: Live/Dead Aqua Cell Stain (ThermoFisher Scientific cat.L34957), CD45RA APC-H7 (clone HI100; BD cat.560674), CCR7 BB700 (clone 3D12; BD cat.566437), PD-1 BV605 (clone EH12.2H7; Biolegend cat.329924), TIGIT eF450 (clone MBSA43; eBioscience cat.48-9500-42), HLA-DR AlexaFluor700 (clone G46-6; BD cat.560743), ICOS BV785 (clone C398.4 A; Biolegend cat.313534), α4/CD49d PE-Cy7 (clone 9F10; Biolegend cat.304313) and β1/CD29 BB515 (clone MAR4; BD cat.564565). Cells were simultaneously fixed and permeabilized with the FoxP3 Buffer Set (eBioscience), followed by intracellular staining of HIV p24 with clone 28B7 APC (MediMabs cat.MM-0289-APC) and clone KC57 PE (Beckman Coulter cat.6604667). All samples were resuspended at a final concentration of 1 × 106 cells/ml in PBS and filtered prior to cell sorting.
Dufour C., Richard C., Pardons M., Massanella M., Ackaoui A., Murrell B., Routy B., Thomas R., Routy J.P., Fromentin R, & Chomont N. (2023). Phenotypic characterization of single CD4+ T cells harboring genetically intact and inducible HIV genomes. Nature Communications, 14, 1115.
Full text: Click here
Publication 2023
Antibodies Brefeldin A Buffers CD4 Positive T Lymphocytes Cells Clone Cells HIV Core Protein p24 HLA-DR Antigens ICOS protein, human Ionomycin Lamivudine Protoplasm Raltegravir Stains TIGIT protein, human
3
Antiretroviral Therapy in Murine HIV
Cited 1 time

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Emtricitabine Infection Mice, House Raltegravir Tenofovir
4
SIV Infection and ART Therapy in Rhesus Macaques
Chinese rhesus macaques (n = 18) that were confirmed to be seronegative for SIV, STLV-1 (simian T leukemia virus type 1), SRV-1 (simian type D retrovirus 1) and herpes B viruses were infected with SIVmac251 at 10 AID50 intravenously. Four days post-infection, 11 out of 18 animals were treated daily with tenofovir (TFV, 20 mg/kg; Gilead, Foster City, CA, USA) and emtricitabine (FTC, 40 mg/kg; Gilead) subcutaneously and raltegravir (RAL, 20 mg/kg; Merck, Kenilworth, NJ, USA) or dolutegravir (DTG, 5 mg/kg; ViiV, London, UK) and ritonavir (RTV, 20 mg/kg; Abbvie, North Chicago, IL, USA) orally, as previously described [48 (link)]. From the 11 ART-treated animals, n  =  3 received ART for the duration of the study until they had an undetectable plasma viral load and were euthanized at that time (SIV[+]/ART). n  =  8 had analytic therapy interruption (SIV[+]/ATI) at different time points after SIV suppression, and the animals were euthanized when they had a detectable plasma viral load. This duration varied from 10 to 28 days, with two animals requiring 159 and 161 days to rebound. Several animals (n = 7) did not receive ART (SIV[+]) and were euthanized 38 to 104 days post-infection. The animals were sacrificed at different time points post-infection, and the harvesting of the plasma, CSF and brain was performed immediately after the sacrifice [48 (link)].
Mohammadzadeh N., Zhang N., Branton W.G., Zghidi-Abouzid O., Cohen E.A., Gelman B.B., Estaquier J., Kong L, & Power C. (2023). The HIV Restriction Factor Profile in the Brain Is Associated with the Clinical Status and Viral Quantities. Viruses, 15(2), 316.
Full text: Click here
Publication 2023
Animals Brain Herpesvirus 1, Cercopithecine Infection Leukemogenic Viruses Macaca mulatta lasiota Plasma Raltegravir Simian retrovirus 1 Simian T-lymphotropic virus 1 Tenofovir Therapeutics
5
Quantitative Viral Outgrowth Assay for HIV-1
HIV-1 p24 protein production (replication-competent virus as measure of infectious particles production) was analyzed in quantitative viral outgrowth assays (QVOA) (19 (link), 41 (link)) after rCD4 T cells’ ex vivo exposure to N-BPs PAM and Zol. Briefly, magnetically isolated rCD4 (CD3+/CD4+/CD69−/ CD25−/ HLA−DR−) T cells (Stemcell Technologies) were rested in the presence of antiretroviral drugs (10nM Raltegravir and 20nM Efavirenz). Cells were washed, counted and plated in limiting dilution from 1×106 to 0.1×106 cells. Cells were left untreated or exposed 24 hours to PHA and IL-2, or to N-BPs PAM, Zol and ALN. After washing, isolated PHA-activated CD4 cells from uninfected individuals were added twice during the 19-day culture as targets of new infections to outgrowth the virus. After 15 days of culture, supernatants were harvested and HIV-1p24 ELISA performed and confirmed at day 19 of culture. The frequency of infection was calculated and expressed as infectious units per million (IUPM) cultured cells, as explained in Statistical Methods.
Sanz M., Weideman A.M., Ward A.R., Clohosey M.L., Garcia-Recio S., Selitsky S.R., Mann B.T., Iannone M.A., Whitworth C.P., Chitrakar A., Garrido C., Kirchherr J., Coffey A.R., Tsai Y.H., Samir S., Xu Y., Copertino D., Bosque A., Jones B.R., Parker J.S., Hudgens M.G., Goonetilleke N, & Soriano-Sarabia N. (2023). Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1. bioRxiv.
Full text: Click here
Publication Preprint 2023
Biological Assay CD4 Positive T Lymphocytes Cells Cultured Cells DNA Replication efavirenz Enzyme-Linked Immunosorbent Assay HIV-1 HLA-DR Antigens IL2RA protein, human Infection Pharmaceutical Preparations Proteins Raltegravir Retinal Cone Dystrophy 4 Stem Cells T-Lymphocyte Technique, Dilution Virion Virus

Top products related to «Raltegravir»

1
Raltegravir by Merck Group
Sourced in United States
Raltegravir is a laboratory product manufactured by Merck Group. It is an integrase inhibitor, a class of antiretroviral drugs used in the treatment of HIV infection.
2
Raltegravir by Selleck Chemicals
Raltegravir is a laboratory analytical instrument used for the detection and quantification of the HIV integrase inhibitor drug raltegravir. It is a sensitive and specific tool for researchers and scientists working in the field of HIV/AIDS research and drug development.
3
Ionomycin by Merck Group
Sourced in United States, Germany, United Kingdom, Macao, France, Italy, China, Canada, Switzerland, Sao Tome and Principe, Australia, Japan, Belgium, Denmark, Netherlands, Israel, Chile, Spain
Ionomycin is a laboratory reagent used in cell biology research. It functions as a calcium ionophore, facilitating the transport of calcium ions across cell membranes. Ionomycin is commonly used to study calcium-dependent signaling pathways and cellular processes.
4
Phorbol myristate acetate (pma) by Merck Group
Sourced in United States, Germany, United Kingdom, France, Italy, China, Canada, Switzerland, Sao Tome and Principe, Macao, Poland, Japan, Australia, Belgium, Hungary, Netherlands, India, Denmark, Chile
The PMA is a versatile laboratory equipment designed for precision measurement and analysis. It functions as a sensitive pressure transducer, accurately measuring and monitoring pressure levels in various applications. The PMA provides reliable and consistent data for research and testing purposes.
5
Emtricitabine by Gilead Sciences
Sourced in United States
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) used as part of combination antiretroviral therapy for the treatment of HIV-1 infection. It works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.
6
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
7
Luciferase assay system by Promega
Sourced in United States, Germany, United Kingdom, Australia, Switzerland, Japan, China, France, Sweden, Italy, Spain, Austria, Finland
The Luciferase Assay System is a laboratory tool designed to measure the activity of the luciferase enzyme. Luciferase is an enzyme that catalyzes a bioluminescent reaction, producing light. The Luciferase Assay System provides the necessary reagents to quantify the level of luciferase activity in samples, enabling researchers to study biological processes and gene expression.
8
Raltegravir by Santa Cruz Biotechnology
Sourced in United Kingdom
Raltegravir is a lab equipment product manufactured by Santa Cruz Biotechnology. It is an integrase inhibitor, which functions to prevent the integration of viral DNA into the host cell's DNA, a crucial step in the HIV replication process.
9
Raltegravir ral by Merck Group
Sourced in United States
Raltegravir (RAL) is an antiretroviral medication used in the treatment of HIV infection. It is an integrase strand transfer inhibitor that blocks the enzyme integrase, which is essential for the HIV replication process.
10
Raltegravir by Cayman Chemical
Sourced in United States
Raltegravir is a laboratory research product manufactured by Cayman Chemical. It is a HIV-1 integrase inhibitor.

More about "Raltegravir"

Raltegravir, an integrase inhibitor medication, is a crucial component in the fight against HIV infection.
This antiretroviral drug works by blocking the HIV integrase enzyme, preventing the virus from incorporating its genetic material into the host cell's DNA.
By disrupting this crucial step in the viral replication process, Raltegravir helps reduce the viral load and slow the progression of HIV disease.
Raltegravir has demonstrated efficacy in treating both treatment-naive and treatment-experienced patients, making it a valuable option in the management of HIV.
Researchers can optimize their Raltegravir studies by utilizing PubCompare.ai's AI-powered protocols, which provide access to a wealth of literature, preprints, and patents to identify the most reproducible and precise methods.
PubCompare.ai's intelligent comparisons ensure researchers can experience unparalleled accuracy and effiency in finding the optimal protocols and products for their Raltegravr research.
In addition to Raltegravir, other key compounds and techniques used in HIV research include Ionomycin, a calcium ionophore, and PMA (Phorbol 12-Myristate 13-Acetate), a protein kinase C activator.
These compounds are often used in conjunction with Raltegravir to study the various mechanisms involved in HIV replication and latency.
Emtricitabine, another antiretroviral drug, is also commonly used in combination with Raltegravir to provide a more effective treatment regimen.
The Luciferase Assay System is a widely used tool in HIV research, as it allows for the quantification of viral replication and the evaluation of the efficacy of various antiretroviral drugs, including Raltegravir.
DMSO (Dimethyl Sulfoxide) is another important compound in HIV research, as it is often used as a solvent for various drugs and compounds, including Raltegravir.
By leveraging the insights gained from the MeSH term description and the Metadescription, researchers can optimize their Raltegravir studies and contribute to the ongoing efforts to combat HIV infection and disease progression.